Poultry probiotic vaccine compositions and methods of use thereof

Patent metadata

Field	Value
Publication number	US-10786565-B2
Application number	US-201716311065-A
Country	US
Kind code	B2
Filing date	Jul 11, 2017
Priority date	Jul 11, 2016
Publication date	Sep 29, 2020
Grant date	Sep 29, 2020

Abstract

Provided herein are compositions including a probiotic including at least one strain of live bacteria and a Marek's Disease vaccine. Compositions including a probiotic or a probiotic and a Marek's Disease vaccine may be administered to subjects, including poultry. The compositions may be administered in ovo to increase early lactic acid bacteria in the gastrointestinal tract of the subject, to decrease the gram negative bacteria in the gastrointestinal tract of the subject, to reduce the level of Salmonella in the gastrointestinal tract of the subject and to increase the body weight gain of the subject. Also provided are kits including a probiotic and a Marek's Disease vaccine.

First claim

We claim:

1. A composition comprising a probiotic and a Marek's Disease vaccine, wherein the probiotic comprises a lactic acid bacteria genus selected from the group consisting of Lueconostoc, Staphylococcus, Weissella, Pediococcus and combinations thereof.

2. The composition of claim 1 , further comprising a diluent.

3. The composition of claim 2 , wherein the diluent comprises dimethyl sulfoxide.

4. The composition of claim 2 , wherein the diluent comprises the diluent supplied with the Marek's Disease Vaccine.

5. The composition of claim 2 , wherein the diluent comprises a carbohydrate, a phosphate buffer and NZ amine.

6. The composition of claim 5 , wherein the carbohydrate is sucrose.

7. The composition of claim 1 , wherein the lactic acid bacteria had been selected for gut adaptation in poultry.

8. The composition of claim 1 , wherein the probiotic comprises a lactic acid bacteria from the genus Weissella and a lactic acid bacteria from the genus Pediococcus.

9. The composition of claim 8 , wherein the probiotic comprises a lactic acid bacteria from the species Weissella cibaria , a lactic acid bacteria from the species Pediococcus acidilactici , or both species.

10. The composition of claim 1 , wherein the probiotic comprises one or both of NRRL B-50961 and NRRL B-50964.

11. The composition of claim 1 , wherein the Marek's Disease vaccine comprises a HVT vaccine.

12. The composition of claim 11 , wherein the HVT vaccine comprises the FC-126 strain of turkey herpesvirus.

13. The composition of claim 1 , wherein the Marek's Disease vaccine comprises an attenuated MDV.

14. The composition of claim 13 , wherein the attenuated MDV is selected from the group consisting of SB-1, 301B/1, R2/23 and CVI988.

15. A method of treating a subject comprising administering to the subject any one of the compositions of claim 1 .

16. A kit comprising a probiotic and a Marek's Disease vaccine, wherein the probiotic comprises a lactic acid bacteria genus selected from the group consisting of Lueconostoc, Staphylococcus, Weissella, Pediococcus and combinations thereof.

Assignees

• Univ Arkansas

Inventors

• Teague Kyle D
• Bielke Lisa
• Tellez-Isaias Guillermo
• Hargis Billy

Classifications

• A61K35/747 Primary

  Lactobacilli, e.g. L. acidophilus or L. brevis · CPC title

• A61K2039/552

  Veterinary vaccine · CPC title

• C12N2710/16334

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K35/744

  Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs · CPC title

• A61K39/12

  Viral antigens · CPC title